LYMPHOMAS

In the second part of a 2-article series, Matthew A. Lunning, DO, FACP, leads a discussion on how to best manage toxicities from tafasitamab and lenalidomide for patients with relapsed/refractory diffuse large B-cell lymphoma.

The biologics license application for denileukin diftitox has been resubmitted to the FDA for the treatment of cutaneous T-cell lymphoma after at least 1 prior systemic therapy.

There are currently no FDA-approved agents for relapsed peripheral T-cell lymphoma, and soquelitinib has the potential to fill an unmet need.

In the second part of a 2-article series, Matthew Matasar, MD, MS, discusses long-term follow up data from the LOTIS-2 trial and how these data show the durability and tolerability of loncastuximab for patients with relapsed/refractory diffuse large B-cell lymphoma.

In an interview with Targeted Oncology, Yuqin Song, MD, PhD, discussed golidocitinib as the first JAK1 inhibitor developed for patients with T-cell lymphomas in this pivotal study.

The FDA and Japan’s Ministry of Health, Labor, and Welfare advanced lisocabtagene maraleucel for relapsed/refractory follicular and mantle cell lymphomas.

In the first part of a 2-article series, Matthew A. Lunning, DO, FACP, takes into consideration the perspectives of his peers on the use of tafasitamab and lenalidomide for patients with relapsed/refractory diffuse large B-cell lymphoma.

In an interview with Targeted Oncology, Jie Jin, MD, discussed the need for a standard therapy in peripheral T-cell lymphoma and highlighted the potential impact of the JACKPOT26 study.

Findings from a phase 2 study found that treatment with axicabtagene ciloleucel in relapsed or refractory large B-cell lymphoma led to a complete metabolic response of 71%.

High complete response rates and low incidences of cytokine release syndrome and neurological events were observed when patients with relapsed or refractory mantle cell lymphoma were treated with lisocabtagene maraleucel.

The novel CDK9 inhibitor previously received orphan drug designations in relapsed/refractory acute myeloid leukemia and peripheral T-cell lymphoma.

In the first part of a 2-article series, Matthew Matasar, MD, MS, discusses where loncastuximab fits into the treatment of patients with relapsed/refractory diffuse large B-cell lymphoma and the data that led to the antibody drug conjugate’s approval.

Combining a CDK9 inhibitor with venetoclax and prednisone led to encouraging responses in patients with lymphoid malignancies in the dose-escalation arm of a phase 1 clinical trial.

The ECHELON-2 study compared brentuximab vedotin plus cyclophosphamide, doxorubicin, and prednisone chemotherapy with the standard-of-care cyclophosphamide, doxorubicin, vincristine, and prednisone regimen for CD30- positive T-cell lymphoma.

In an interview with Targeted Oncology, Ann LaCasce, MD, MMSc, delved into the surge of innovations with personalized medicine, advanced technologies, and novel agents for the treatment of patients with lymphomas.

The investigational new drug application of lacutamab, a novel drug for advanced T-cell lymphoma, was put on partial clinical hold after the death of a patient last year.

A study evaluating healthcare expenses identified lisocabtagene maraleucel as a cost-effective second-line treatment for patients with diffuse large B-cell lymphoma.

Mazyar Shadman, MD, MPH, and the Oncology Brothers discuss recent data from SWOG S1826 on nivolumab-AVD in patients aged 60 years and older with advanced stage Hodgkin lymphoma.

Following ASH 2023, Mazyar Shadman, MD, MPH, joins the Oncology Brothers, Rahul Gosain, MD, and Rohit Gosain, MD, to discuss recent data from the ALPINE study investigating zanubrutinib in chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL).

Treatment with zanubrutinib conferred a PFS benefit vs bendamustine plus rituximab across most biomarker subgroups of patients with treatment-naive chronic lymphocytic leukemia or small lymphocytic lymphoma without del(17p), according to findings from the phase 3 SEQUOIA trial.

Responses on the non-covalent BTK inhibitor pirtobrutinib remained high in patients with relapsed chronic lymphocytic leukemia who expressed frequent baseline BTK mutations, according to a genomic analysis of the phase 1/2 BRUIN trial.

DZD8586 showcased antitumor activity and favorable safety with limited grade 3 or greater treatment-emergent adverse effects in patients with heavily pretreated B-cell non-Hodgkin lymphoma, according to preliminary findings from a pooled analysis of two ongoing phase 1 trials.

Stephen Schuster, MD, discusses findings from follow-up of the phase 2 ELARA study presented at the 2023 ASH Annual Meeting.

Investigators report that response-adapted trials utilizing novel combination regimens appear to be safe and feasible in a population of patients with newly diagnosed diffuse large B-cell lymphoma.

Updated safety and subgroup analyses appear consistent with previously reported results from the phase 2 ZUMA-12 study of axicabtagene ciloleucel for patients with high-risk large B-cell lymphoma.

Pirtobrutinib demonstrated promising efficacy and a tolerable safety profile in heavily pretreated patients with relapsed/refractory mantle cell lymphoma who received prior therapy with a covalent BTK inhibitor.

The ongoing LuminICE phase 2 study demonstrated that AFM13 in combination with AB-101 may hold promise for the treatment of patients with relapsed or refractory CD30-positive lymphomas.

Treatment with the oral BTK inhibitor ibrutinib in combination with venetoclax led to a statistically significant improvement in progression-free survival and complete response rate.

Habte Yimer, MD, discusses findings from follow-up data of the phase 3 ALPINE study that were presented at the 2023 ASH Annual Meeting.

Treatment with zanubrutinib, obinutuzumab, and venetoclax, also known as BOVen, showed promising safety and efficacy in treatment-naive patients with TP53-mutant mantle cell lymphoma.